ARTICLE SUMMARY:
The pulse of medtech M&A appears to be quickening as large-caps continue to rely on strategic deals to help drive growth. Here, a closer look at two recently announced deals: Stryker’s proposed $700 million acquisition of Novadaq Technologies and Philips’ $2.2 billion agreement to acquire Spectranetics.
Although critical mass considerations seem to be driving the biggest, most headline-grabbing mergers and acquisitions in medtech today, it’s important not to lose sight of the fact that, for most deals, strategic considerations still matter.
